Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Brian S. Choi"'
Publikováno v:
Leukemia & Lymphoma
Antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with non-Hodgkin lymphoma (NHL) receiving moderately emetogenic chemotherapy (MEC) generally includes a serotonin-type 3 (5-HT3) receptor antagonist (RA). The efficacy and sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac913165ad2dce09c2a1a1d3a5788475
https://doi.org/10.3109/10428194.2013.813498
https://doi.org/10.3109/10428194.2013.813498
Autor:
Jens C. Eickhoff, Dona Alberti, James P. Thomas, Brian S. Choi, Jill M. Kolesar, S. Percy Ivy, George Wilding, Rebecca Marnocha, William R. Schelman, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:973-980
3-AP is a ribonucleotide reductase inhibitor and has been postulated to act synergistically with other chemotherapeutic agents. This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0b3649594d9b53e5685d3a20d6eda61
https://doi.org/10.1007/s00280-010-1250-z
https://doi.org/10.1007/s00280-010-1250-z
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:175-179
To determine the maximum-tolerated dose (MTD) and antitumor activity of twice-weekly gemcitabine when combined with palliative-dose thoracic radiation therapy (RT) in patients with recurrent or progressive lung cancer.Patients were enrolled in a dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe747fa92e68ff24c236715ba729c9f4
https://doi.org/10.1007/s00280-008-0708-8
https://doi.org/10.1007/s00280-008-0708-8
Autor:
Kari Kendra, Jacquelyn A. Hank, David M. King, Paul M. Sondel, KyungMann Kim, David M. Mahvi, Mark R. Albertini, Heidi Schalch, Li Yin Lee, Brian S. Choi, Jacek Gan
Publikováno v:
Cancer Immunology, Immunotherapy. 55:761-774
Purpose: We conducted a phase I trial of interleukin 2 (IL-2) in combination with chimeric 14.18 (ch14.18) and murine R24 antibodies to determine the maximal tolerated dose (MTD), immunological effects, and toxicity of this treatment combination. Exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbaf0cda0cb5d59b3d2a10d78aa78efe
https://doi.org/10.1007/s00262-005-0069-7
https://doi.org/10.1007/s00262-005-0069-7
Autor:
H. Ian Robins, Brian S. Choi
Publikováno v:
Cancer chemotherapy and pharmacology. 61(2)
Described is the first reported case of paclitaxel-induced recurrent laryngeal nerve paralysis in a patient receiving adjuvant therapy for breast cancer. This rare form of neuropathy was reversible at 3 months, but it was re-induced 11 months later w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa1b4d9121dee3eec470db99d1a57493
https://pubmed.ncbi.nlm.nih.gov/18026678
https://pubmed.ncbi.nlm.nih.gov/18026678
Autor:
Brian S. Choi, H. Ian Robins
Publikováno v:
Journal of Clinical Oncology. 25:603-604
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0cddf26e91deed88d5076df3f6f88c0
https://doi.org/10.1200/jco.2006.08.9961
https://doi.org/10.1200/jco.2006.08.9961
Autor:
Kyle D. Holen, Jill M. Kolesar, James P. Thomas, W. Antholine, Jens C. Eickhoff, Greg Wilding, Brian S. Choi, Rebecca Marnocha, William R. Schelman, D. Alberti
Publikováno v:
Journal of Clinical Oncology. 26:2527-2527
2527 Background: T is a small molecule inhibitor of ribonucleotide reductase (RR) and has been postulated to act synergistically with I. This study was conducted to determine the toxicity and antitumor activity of T with I. Correlative studies includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6c3de9adae84284deee70a8434ce072
https://doi.org/10.1200/jco.2008.26.15_suppl.2527
https://doi.org/10.1200/jco.2008.26.15_suppl.2527